Clinical Trials

920 enrolled

Breast Neoplasms, Neoplasm Metastasis

NCT06757634 2026-05-18

Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)

1,180 enrolled

Breast Neoplasms, Neoplasm Metastasis

NCT06380751 2026-05-15

EvoPAR-BR01

500 enrolled

Advanced Breast Cancer

NCT06982521 2026-05-08

ReDiscover-2

540 enrolled

Breast Neoplasms

NCT05646862 2026-05-06

INAVO121

420 enrolled

Breast Neoplasms

NCT07062965 2026-05-06

A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.

400 enrolled

Unilateral Breast Neoplasms, Breast Neoplasms, Recurrence

NCT06065748 2026-05-05

A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)

1,050 enrolled

Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer

NCT04305496 2026-04-30

CAPItello-291

818 enrolled 19 charts 1 FDA

Locally Advanced (Inoperable) or Metastatic Breast Cancer

NCT05306340 2026-04-30

A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)

373 enrolled

Breast Neoplasms

NCT05696626 2026-04-21

ELAINEIII

500 enrolled

Breast Neoplasms

NCT05038735 2026-04-08

EPIK-B5

234 enrolled

Breast Neoplasms

NCT06764186 2026-04-08

CAPItana

101 enrolled

Breast Neoplasms

NCT04851613 2026-04-02

Study to Evaluate Efficacy & Safety of Afuresertib Plus Fulvestrant in Patients With Locally Advanced or Metastatic HR+/HER2- Breast Cancer

256 enrolled

Breast Neoplasms

NCT06954961 2026-03-31

A Study to Evaluate D-0502 in Subjects With ER+ Her2- Locally Advanced or Metastatic Breast Cancer

640 enrolled

Breast Neoplasms

NCT06635447 2026-03-27

CAPItrue

258 enrolled

Breast Neoplasms, Disease Progression

NCT00099437 2026-03-18

CONFIRM

736 enrolled 14 charts

Breast Neoplasms

NCT05654623 2026-03-18

VERITAC-2

624 enrolled 17 charts 1 FDA

Breast Neoplasms

NCT06016738 2026-03-13

OPERA-01

510 enrolled

Breast Neoplasms

NCT01602380 2026-02-27

FALCON

462 enrolled 20 charts

Tumor-Agnostic

Neoplasm Metastasis, Neoplasms

NCT05501886 2026-02-10

VIKTORIA-1

701 enrolled

Phase 3 Not yet recruiting

Breast Neoplasms, Neoplasm Metastasis

NCT07393321 2026-02-06

A Phase III Clinical Trial of NTQ1062 in Combination With Fulvestrant for the Treatment of Advanced or Metastatic HR+/HER2- Breast Cancer

210 enrolled

Breast Neoplasms

NCT02763566 2026-02-05

MONARCH plus

463 enrolled 20 charts

Breast Neoplasms

NCT07024173 2026-01-26

A Phase 3 Study of HRS-8080 Versus Treatment Chosen by Physicians in Locally Advanced and Metastatic Breast Cancer

240 enrolled

Breast Neoplasms

NCT05169567 2026-01-16

postMONARCH

368 enrolled 14 charts

Breast Neoplasms, Neoplasm Metastasis

NCT05365178 2026-01-07

To Evaluate the Efficacy and Safety of TQB3616 in Combination With Fulvestrant Versus Placebo in Combination With Fulvestrant in Previously Untreated Hormone-receptor (HR)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Advanced Breast Cancer

432 enrolled

HR-positive, HER2-negative Breast Neoplasms

NCT07207070 2025-12-30

A Randomised, Open-label, Multicentre Phase III Clinical Study to Evaluate the Efficacy and Safety of JS105 Combined With Dalpiciclib and Fulvestrant Compared With Dalpiciclib and Fulvestrant in Patients With PIK3CA-mutated, HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer.

312 enrolled

Breast Neoplasms

NCT02107703 2025-10-21

MONARCH 2

669 enrolled 22 charts

Breast Neoplasms

NCT06680921 2025-09-22

A Study of SIM0270 Combined With Everolimus vs. Treatment of Physician's Choice in Patients With ER+/HER2- Advanced Breast Cancer (SIMRISE)

460 enrolled

Breast Neoplasms

NCT03778931 2025-09-15

EMERALD

478 enrolled 16 charts 1 FDA

Breast Neoplasms

NCT04975308 2025-07-11

EMBER-3

874 enrolled 29 charts 1 FDA

Breast Neoplasms, Neoplasm Metastasis

NCT06998108 2025-05-31

Study of BEBT-209 in Combination With Fulvestrant Versus Placebo in Combination With Fulvestrant in Patients With HR+/HER2- Locally Advanced or Metastatic Breast Cancer Who Have Progressed After Prior Endocrine Therapy

330 enrolled

Phase 3 Not yet recruiting

Breast Neoplasms

NCT06929325 2025-04-16

Sirolimus for Injection (Albumin-bound) Combined With Fulvestrant for HR+/HER2- Advanced/Metastatic Breast Cancer Patients Previously Treated With CDK4/6 Inhibitors

312 enrolled

Breast Neoplasms

NCT02437318 2025-02-13

SOLAR-1

572 enrolled 22 charts 1 FDA

BreastEndocrine

Breast Neoplasms, Neoplasms, Multiple Endocrine Neoplasia Type 1

NCT05054751 2024-10-10

GB491 Combined With Fulvestrant for HR+ HER2- Locally Advanced or Metastatic Breast Cancer

275 enrolled

Breast Neoplasms

NCT03439046 2024-08-01

BioItaLEE

287 enrolled

Breast Neoplasms, Hereditary Sensory and Autonomic Neuropathies

NCT05077449 2024-05-24

A Study of XZP-3287 in Combination With Fulvestrant in Patients With Advanced Breast Cancer

300 enrolled

Breast Neoplasms

NCT01942135 2024-04-04

Palbociclib (PD-0332991) Combined With Fulvestrant In Hormone Receptor+ HER2-Negative Metastatic Breast Cancer After Endocrine Failure (PALOMA-3)

521 enrolled 31 charts

Breast Neoplasms

NCT05065411 2024-02-26

VERU-024

Phase 3 Terminated

5 enrolled

Breast Neoplasms

NCT02422615 2023-11-30

MONALEESA-3

726 enrolled 17 charts 1 FDA

BreastEndocrine

Breast Diseases, Breast Neoplasms, Neoplasms, Neoplasms by Site, Multiple Endocrine Neoplasia Type 1

NCT05433480 2023-07-27

A Study of BPI-16350 in Combination With Fulvestrant in Patients With HR+ and HER2- Locally Advanced, Recurrent or Metastatic Breast Cancer

Phase 3 Unknown

274 enrolled

Breast Neoplasms

NCT03462251 2023-01-19

RIBBIT

41 enrolled

Breast Neoplasms

NCT02340221 2022-07-12

SANDPIPER

Phase 3 Terminated

631 enrolled 49 charts

Breast Neoplasms

NCT03927456 2021-06-03

A Study of SHR6390 in Combination With Fulvestrant in Patients With HR Positive and HER2 Negative Advanced Breast Cancer

Phase 3 Unknown

357 enrolled

Advanced Breast Cancer

NCT01610284 2020-08-25

BELLE-2

1,147 enrolled 20 charts

Breast Neoplasms, Neoplasm Metastasis

NCT01633060 2019-01-30

BELLE-3

Phase 3 Terminated

432 enrolled 20 charts

Breast Neoplasms, Neoplasm Metastasis, Hereditary Sensory and Autonomic Neuropathies

NCT01300351 2015-04-24

Comparing the Efficacy and Tolerability of Fulvestrant 500 mg Versus 250 mg in Advanced Breast Cancer Women

249 enrolled 16 charts

Breast Neoplasms

NCT00065325 2015-02-24

EFECT

694 enrolled

Breast Neoplasms

NCT00256698 2012-08-01

FACT

514 enrolled 13 charts

Breast Neoplasms, Neoplasms, Recurrence

NCT00241449 2012-06-06

A Trial Comparing the Efficacy and Tolerability of Faslodex With Nolvadex in Postmenopausal Women With Advanced Breast Cancer

51 enrolled